UNSPSC 51201901: Glatiramer acetate

This classification denotes a biological response modifier with the molecular formula (C9H9NO2)n.(C6H12N2O)n.(C5H7NO3)n.(C3H5NO)n.C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5M691HL4BO, chemically known as l-glutamic acid polymer with l-alanine, l-lysine and l-tyrosine, acetate (salt) but generally known as glatiramer acetate, which bears US NIH Compound Identifier 3081884. European Medicines Agency schedules Glatiramer acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13971MIG.

UNSPSC 51201901 Glatiramer acetate is a Commodity code for a disease-modifying pharmaceutical agent used to treat multiple sclerosis, but recent state and local contract opportunities tagged under this code show no procurement activity aligned with the pharmaceutical product itself. Instead, the opportunities reflect a significant mismatch between the code classification and actual buying activity. The City of Tucson posted an RFP (due June 9, 2026) for athletic training services for fire and police departments, requiring NATA BOC and NSCA TSAC-F certified trainers with physician supervision, covering injury prevention, rehabilitation, fitness evaluation, and return-to-duty support with a one-year initial term and four optional one-year extensions. The City of Tampa issued an ITB (due April 9, 2025) for medical aid supplies including antiseptic sprays, hydrogen peroxide, aspirin, bandages, and first aid kits for the Fire Rescue Department, with annual quantities ranging from 1 to 2,700 units per item, a $100,000 departmental budget, and set-asides for Small Local Business Enterprises and Underutilized Woman and Minority Owned Business Enterprises offering up to 5% bid discounts. The Texas Health and Human Services Commission posted an RFI (due April 3, 2026) seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to establish direct contracting between the state pharmacy benefit program and manufacturers outside traditional pharmacy benefit manager arrangements.

The code shows minimal activity supporting pharmaceutical procurement and no issuing bodies actively soliciting glatiramer acetate or therapeutically equivalent disease-modifying agents. The three recent opportunities span fire departments and public safety agencies in Arizona, Florida, and a state health commission, but none target injectable or oral pharmaceutical supplies aligned with the UNSPSC category definition. Buyers in Tucson, Tampa, and Texas are procuring athletic training labor, commodity medical supplies, and pharmacy program infrastructure rather than specialty pharmaceuticals. This code warrants close watch to determine whether misclassification of opportunities persists or whether state and local purchasing of glatiramer acetate and related specialty drugs occurs under alternative UNSPSC codes or through cooperative purchasing vehicles not captured in the recent-opportunities block.